Filtered By:
Specialty: Neurology
Condition: Allergy
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 65 results found since Jan 2013.
Muscle Selection Patterns for Injection of OnabotulinumtoxinA in Adult Patients with Post-Stroke Lower-Limb Spasticity Influence Outcome: Results from a Double-Blind, Placebo-Controlled Phase 3 Clinical Trial (S7.001)
Conclusions:Additional injections of onabotulinumtoxinA into the toe flexors (FDL, FHL) significantly improved ankle MAS and CGI scores compared with injections into the mandatory muscles alone, particularly when treatment was initiated >2 years post-stroke. Study Supported by: Allergan, Inc.Disclosure: Dr. Wein has received research support from Allergan, Bayer, Accorda, Astra Zeneca, and the National Institutes of Health. Dr. Esquenazi has received research support from Allergan and Ipsen. Dr. Ward has received personal compensation for activities with Allergan and Ipsen. Dr. Geis has received personal compensation fo...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Wein, T., Esquenazi, A., Ward, A., Geis, C., Liu, C., Dimitrova, R. Tags: Stroke Clinical Trials Source Type: research
Sustained Benefit with Repeated Treatments of OnabotulinumtoxinA in Post-Stroke Lower Limb Spasticity: 1-Year Open-Label Final Results from a Double-Blind, Placebo-Controlled, Phase 3 Trial (S7.002)
Conclusions:Improvements in MAS, CGI, and GAS scores were consistent and increased with repeated treatments of onabotulinumtoxinA over 1 year in patients with PSLLS. Study Supported By: AllerganDisclosure: Dr. Wein has received research support from Allergan, Bayer, Accorda, Astra Zeneca, and the National Institutes of Health. Dr. Geis has received personal compensation for activities with Allergan as a researcher and speaker. Dr. Ayyoub has received research support from Allergan, Merz, and Ipsen. Dr. Ochudlo has nothing to disclose. Dr. James has received personal compensation for activities with Allergan as an employee....
Source: Neurology - April 3, 2016 Category: Neurology Authors: Wein, T., Geis, C., Ayyoub, Z., Ochudlo, S., James, L., Pan, G., Bogucki, A., Dimitrova, R. Tags: Stroke Clinical Trials Source Type: research
CT-Based Collateral Scoring Can Predict Ischemic Penumbra Volume in Acute Ischemic Stroke (P2.330)
Conclusion: A CS grading system comparing collaterals in the symptomatic hemisphere to the contralateral side accurately predicted MRI lesion volume and ischemic penumbra ratio in AIS patients. Because this system can be performed in community-based settings, it holds promise as a means of identifying patients requiring urgent transfer to a referral stroke center for interventional care.Disclosure: Dr. O'Donnell has nothing to disclose. Dr. Majersik has nothing to disclose. Dr. Chung has nothing to disclose. Dr. Smith has received personal compensation for activities with CSL Behring, Grifols, and Allergan. Dr. Smith has r...
Source: Neurology - April 3, 2016 Category: Neurology Authors: O'Donnell, S., Majersik, J., Chung, L., Smith, A. G., Dunleavy, B., De Havenon, A. Tags: Acute Endovascular: The Need for Speed Source Type: research
Inpatient versus Outpatient Management of TIA or Minor Stroke: Clinical Outcome (P6.035)
Conclusion These findings suggest that routine hospitalization of patients with TIA or minor ischemic stroke does not positively affect short-term clinical outcome. Disclosure: Dr. Rothrock has received personal compensation for activities with Allergan and Boehringer-Ingleheim. Dr. Majidi has nothing to disclose. Dr. Burger has nothing to disclose. Dr. Leon-Guererro has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Rothrock, J., Majidi, S., Burger, K., Leon-Guererro, C. Tags: Telestroke and Other Innovations and TIA Source Type: research
Baseline Demographics and Clinical Characteristics of Patients Treated for Spasticity in the Adult Spasticity International Registry (ASPIRE Study) (P3.296)
Conclusions: Global epidemiological data for spasticity is lacking. ASPIRE represents the largest existing international database prospectively evaluating demographics and clinical characteristics of spasticity across multiple etiologies. Further baseline analyses will describe onabotulinumtoxinA utilization patterns, treatment satisfaction, individual/caregiver burden, and characterize the healthcare provider population treating spasticity.Disclosure: Dr. Franciso has received personal compensation for activities with Allergan as a consultant. Dr. Bandari has received personal compensation for activities with Accorda, All...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Francisco, G., Bandari, D., Bavikatte, G., Jost, W., Manack Adams, A., Largent, J., Esquenazi, A. Tags: Neurorehabilitation Source Type: research
Sustained Efficacy with IncobotulinumtoxinA in Upper-Limb Post-Stroke Spasticity Over 48 Weeks (a Phase 3, Placebo-Controlled Study with an Open-Label Extension) (P3.303)
Conclusions: For subjects with upper-limb spasticity after a stroke, repeated injections of incobotulinumtoxinA (400U each at 12-week intervals) showed sustained efficacy in reducing muscle tone and spasticity-associated disability, while confirming the favorable safety profile of incobotulinumtoxinA in this indication.Disclosure: Dr. Elovic has received personal compensation from Allergan, Inc., and Solstice Neurosciences. Dr. Brashear has received personal compensation for activities with Allergan, Ipsen, Revance and Concerta as a consultant. Dr. Brashear has received royalty payments from books royalties. Dr. Brashear h...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Elovic, E., Brashear, A., Munin, M., Kaňovsky, P., Hanschmann, A., Hiersemenzel, R., Marciniak, C. Tags: Neurorehabilitation Source Type: research
Extension Study to Assess the Safety and Efficacy of Repeated AbobotulinumtoxinA Injections in Adults with Upper Limb Spasticity (P3.307)
Conclusions: Safety analysis in this long term study did not generate any new unexpected safety findings; safety profile was similar across doses. Repeated abobotulinumtoxinA injections were associated with sustained or progressive improvement in muscle tone, perceived function (DAS) and global assessment in ULS patients post stroke/TBI. Supported by:IpsenDisclosure: Dr. Brashear has received personal compensation for activities with Allergan, Ipsen, Revance and Concerta as a consultant. Dr. Brashear has received royalty payments from books royalties. Dr. Brashear has received research support from Ipsen, Merz, Allerg Dr. ...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Brashear, A., Marciniak, C., Edgley, S., Gul, F., Hedera, P., McAllister, P., O'Dell, M., Rubin, B., Walker, H., Vilain, C., Mahmood, A., Gracies, J.-M. Tags: Neurorehabilitation Source Type: research
PRISM II: Effectiveness of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(R)) for Treatment of Pseudobulbar Affect Secondary to Dementia, Stroke, or Traumatic Brain Injury: Combined Results of a Multicenter Open-Label Study (P2.225)
Conclusion: The open-label PRISM II study supports DM/Q effectiveness for PBA irrespective of underlying etiology. Study supported by: Avanir Pharmaceuticals, Inc.Disclosure: Dr. Siffert has nothing to disclose. Dr. Hammond has nothing to disclose. Dr. Alexander has nothing to disclose. Dr. Cutler has received personal compensation for activities with Abbott, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Lilly, Merck, Novartis, Ortho-McNeil-Janssen, Otsuka, Pamlab, Pfizer, Shire, and Sunovion. Dr. D'Amico has received personal compensation for activities with Avanir Pharmaceuticals, Inc. Dr. Doody has receive...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Siffert, J., Hammond, F., Alexander, D., Cutler, A., D'Amico, S., Doody, R., Sauve, W., Zorowitz, R., Davis, C., Shin, P., Ledon, F., Yonan, C., Formella, A. Tags: Aging and Dementia: Therapeutics Source Type: research
Impact of Early Intervention with OnabotulinumtoxinA Treatment in Adult Patients with Post-Stroke Lower Limb Spasticity (S31.006)
Conclusions:OnabotulinumtoxinA 300-400U is effective in improving MAS, CGI, and GAS scores in patients with PSLLS with greater benefits among those who initiate treatment ≤24 months post-stroke. Study Supported by: Allergan, Inc.Disclosure: Dr. Patel has personal compensation for activities with Allergan as a speaker. Dr. Patel has received research support from Allergan, Inc., Merz Pharma, and Ipsen. Dr. Ward has received personal compensation for activities with Allergan and Ipsen. Dr. Geis has received personal compensation for activities with Allergan as a researcher and speaker. Dr. Liu has received personal compen...
Source: Neurology - February 7, 2016 Category: Neurology Authors: Patel, A., Ward, A., Geis, C., Liu, C., Jost, W., Dimitrova, R. Tags: Stroke Risk, Outcomes, and Complications Source Type: research
FDA Approves Botox for Lower Limb Spasticity FDA Approves Botox for Lower Limb Spasticity
The FDA has approved a new indication for Allergan's Botox (onabotulinumtoxinA): lower limb spasticity seen after stroke and in other neurologic disorders. FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - January 26, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Teaching NeuroImages: Hyperintense acute reperfusion marker in ischemic stroke with transient symptoms
A 67-year-old man with 45-minute onset left hemiparesis underwent 3.0T gadolinium-enhanced MRI (reported iodine contrast allergy) with right frontoparietal small infarcts on diffusion-weighted images without vascular obstruction. No reperfusion therapy was given due to complete spontaneous symptoms regression. Twenty-four hours later, a second MRI showed right parietal CSF space enhancement on fluid-attenuated inversion recovery. Neither MRI nor CT had sign of hemorrhage (figure).
Source: Neurology - January 11, 2016 Category: Neurology Authors: Patroclo, C. B., Picanco, M. R., Bandeira, A. C. N., Carvalho, V. S. d., Bezerra, D. d. C. Tags: All Imaging, MRI, Embolism, Infarction, Subarachnoid hemorrhage RESIDENT & amp;amp; FELLOW SECTION Source Type: research
Stroke in a global world: geographical differences in stroke subtypes and age at onset in two different populations from Europe and South America. (P1.094)
CONCLUSIONS: Changes in the prevalence of vascular risk factors and stroke subtypes can be expected with the ageing of populations. In order to reduce age and stroke-related burden, public health strategies should be implemented. Study Supported by:Disclosure: Dr. Casanova-Lanchipa has nothing to disclose. Dr. Carod has received personal compensation for activities with Allergan, Merck Sharp & Dohme, Lundbeck Research USA, Inc., Biogen Idec, Esteve, and Pfizer as a scientific advisory board member and/or speaker. Dr. Cruz-Ramirez has nothing to disclose. Dr. Sanchez-Perez has nothing to disclose. Dr. Siacara-Aguayo has...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Casanova-Lanchipa, J., Carod, F., Cruz-Ramirez, L. M., Sanchez-Perez, N., Siacara-Aguayo, F., Gomez-Moreno, I., Gomez Romero, L., Coral, L., Trizotto, D., Moreira, C. Tags: Neuroepidemiology: Cerebrovascular Disease, Critical Care, Epilepsy, Child Neurology, and Sleep Source Type: research
The Role of Discharge Disposition in the Interventional Management of Stroke (IMSIII) Trial (P1.062)
CONCLUSIONS:Subjects who were discharged home or to an IRF were significantly associated with having a favorable outcome compared to those who were discharged to a SNF.Disclosure: Dr. Belagaje has nothing to disclose. Dr. Gupta has received personal compensation for activities with Stryker Neurovascular, Rapid Medical, and Covidien. Dr. Foster has nothing to disclose. Dr. Kissela has received personal compensation for activities with Allergan, Inc., AbbVie, and Reata Pharmaceuticals. Dr. Broderick has received personal compensation for activities with Pfizer as a consultant. Dr. Broderick has received research support from Genentech Inc.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Belagaje, S., Gupta, R., Foster, L., Kissela, B., Broderick, J. Tags: Cerebrovascular Disease and Interventional Neurology: Epidemiology Source Type: research
Childhood stroke: comparison of strokes identified in administrative databases with those identified in a population-based study (P1.072)
Conclusions: We found differences in distribution of both age and stroke type between a population-based physician-confirmed child stroke database and those identified through two administrative databases using ICD-9 codes having large positive predictive value. It appears there may be uncertainty regarding coding of stroke events in administrative databases. Using data obtained from physician-verified databases is optimal for inferential analysis.Disclosure: Dr. Taylor has nothing to disclose. Dr. Khoury has nothing to disclose. Dr. Xu has nothing to disclose. Dr. Sucharew has nothing to disclose. Dr. Alwell has nothing t...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Taylor, J., Khoury, J., Xu, Y., Sucharew, H., Alwell, K., Moomaw, C., Horn, P., Yeramaneni, S., Peariso, K., Khatri, P., Broderick, J., Kissela, B., Kleindorfer, D. Tags: Cerebrovascular Disease and Interventional Neurology: Epidemiology Source Type: research
Digital Subtraction Angiography (DSA) Arch Run in Place of CT Vessel and Perfusion Imaging: Proof of Concept (P1.014)
CONCLUSIONS: In both cases, DSA arch runs generated adequate, rapid vessel imaging including demonstration of collaterals in place of CTA/CTP. This minimized delays in treatment, provided information key to predicting benefit and facilitated a shorter time to reperfusion. This is proof of concept, that DSA arch runs can be used in place of CTA/CTP in patients likely to require intra-arterial therapy.Disclosure: Dr. Campbell has nothing to disclose. Dr. Jadhav has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Campbell, D., Jadhav, A. Tags: Cerebrovascular Disease and Interventional Neurology I ePosters Source Type: research
